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Summary Inhibition of clonogenic potential by the glycinamideribonucleosyl transformylase inhibitor 5,10-
dideazatetrahydrofolic acid (DDATHF, Lometrexol) was evaluated in vitro in a human ovarian carcinoma cell
line, SW626. Drug-induced inhibition of clonogenic potential is a function of the dose and time of exposure
and is independent of the formation of DNA single-strand breaks or de novo synthesis of protein. Simul-
taneous treatment with 1OOiLM hypoxanthine completely prevented the inhibition of clonogenic potential
caused by 0.5 ILM DDATHF. DDATHF blocked cells in the early-middle S-phases of the cell cycle, and there
was a correponding marked reduction in the rate of DNA synthesis after drug withdrawal. The cytotoxic
potential of DDATHF was modulated by the folic acid concentration present in the medium. In a medium
containing 0.22 gM folic acid, DDATHF cytotoxicity was at least 100 times that in a regular medium
containing 2.221LM folic acid, levels which, however, are about 100 times those found in human plasma.
DDATHF cytotoxicity differed moderately when folic acid concentrations varied between 0.22 and 011M,
suggesting that folic acid does not necessarily antagonise DDATHF anti-tumour activity. Folinic acid at a
concentration as low as 0.1IJM can completely rescue cells when given simultaneously with 0.5 gAM DDATHF.
When folinic acid was given 24 h after DDATHF, a reversal of cytotoxicity was observed at 0.5 and I gAM, but
to a much lesser extent than simultaneous treatment. When folinic acid was added after 48 or 72 h of
DDATHF washout, even at a high concentration and for a long time, no reduction in DDATHF cytotoxicity
was found. In conclusion, the study highlights the modulation of DDATHF cytotoxicity by folic acid or by
folinic acid and provides further rationale for in vivo clinical investigation with these combinations.
5,10-Dideazatetrahydrofolic acid (DDATHF, Lometrexol) is
an anti-cancer agent under early clinical investigation in
Europe and in the USA. It is the first clinically investigated
antifolate whose mode of action is related to the inhibition of
glycinamideribonucleosyl (GAR) transformylase, a key
enzyme in the de novo synthesis of purines (Moran et al.,
1985; Beardsley et al., 1989; Taylor et al., 1989; Baldwin et
al., 1991). Many aspects of the cellular pharmacology of
DDATHF have already been investigated in detail.
DDATHF appears to be a good substrate for membrane
folate-binding proteins (mFBP) (Kane et al., 1988; Jansen et
al., 1991; Westerhof et al., 1991), which probably act as a
relevant carrier for its intracellular transport. The intracel-
lular transport can also be mediated by the reduced folate
carrier (Pizzorno et al., 1993). Once in the cell, DDATHF is
efficiently biotransformed to polyglutamated metabolites,
which are much more potent inhibitors of GAR transfor-
mylase than the monoglutamated parent compound (Piz-
zorno et al., 1991a).
What is not yet known is the mechanism of cytotoxicity
consequent to GAR transformylase inhibition. Like other
antifolates (Lorico et al., 1988) DDATHF could cause DNA
damage, which will eventually result in cell death, but this
hypothesis requires experimental verification.
During phase I clinical studies DDATHF showed severe
and unexpected haematological and gastrointestinal toxicity
in some patients (Muggia et al., 1990; Sessa et al., 1990; Ray
et al., 1992). Two approaches are currently under clinical
investigation to reduce the risk of toxicity: (i) the con-
comitant administration of folic acid and (ii) the use of
folinic acid as an antidote. Both approaches are based on
findings in mice, but the mechanism by which folic and
folinic acid counteract DDATHF-induced toxicity is not yet
clear (Alati et al., 1992; Grindey et al., 1992).
The aim of this study was to investigate whether and how
DDATHF affects the normal cell cycle distribution and
DNA integrity of tumour cells exposed to cytotoxic concent-
rations of the drug and to obtain information on the
influence of folic and folinic acid on the drug cytotoxicity.
Materials and methods
Cells andculture conditions
The SW626 human ovarian carcinoma cell line was used (Sen
et al., 1990). For all these experiments cells were grown as
monolayers in RPMI-1640 medium supplemented with 10%
dialysed fetal bovine serum (FBS) (cut-off point 3,500 Da). In
order to assess the role offolic acid in the medium, cells were
grown in. progressively lower folate-containing media. From
normal RPMI-1640 containing 2.2 lM folic acid, the cells
were conditioned to grow in low-folate medium by reducing
the folic acid concentration from 2.2 gsm to 0.22 iAM in at
least six passages, then stepwise from 0.22 to 0.11 to 0.05 to
0.025 to 0.0125 liM. From the last passage, cells were condi-
tioned to grow in completely folate-free conditions in at least
six passages. Under low-folate conditions, the cells grew
normally; the doubling time and cell morphology remained
unaffected. The doubling time of SW626 cells after appropri-
ate adaptation in different medium was 23 h in medium
containing normal serum and 2.27 tLM folic acid, 23 h in
medium containing dialysed serum and 2.27 tLM folic acid,
23 h in medium containing dialysed serum and 0.22 ftM folic
acid in 25 h in medium containing dialysed serum and 0gLM
folic acid. During conditioning in complete folate-free
medium, the size of the cells increased initially and their
doubling time also increased, but after a few passages in this
folate-free medium, they regained their original morphology
and started growing, as in the presence of folate.
Reagents and culture ware
5,10-Dideazatetrahydrofolic acid (DDATHF) (batch
235MH8) was obtained from Eli Lilly (Indianapolis, IN,
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USA). Folinic acid (batch LFP956) was provided by
Cyanamid Italia. Methotrexate was obtained from the Drug
Synthesis and Chemistry Branch, Division of Cancer Treat-
ment, National Cancer Insititute, Bethesda, MD, USA.
RPMI-1640 medium and custom prepared folic acid-free
RPMI-1640 medium (Cat. No. 041-90735 M) were purchased
from Gibco Europe, Paisley, UK. Fetal bovine serum (batch
669141) was from Biological Industries, Israel. Cyclohex-
imide, propidium iodide and ribonuclease were purchased
from Calbiochem Corporation. Bromodeoxyuridine (BrdU)
and goat anti-mouse IgG conjugated with fluorescein
isothiocyanate (FITC) were purchased from Sigma (St Louis,
MO, USA). Anti-BrdU was from Becton Dickinson (Moun-
tain View, CA, USA) and normal goat serum was a product
of Dakopatts, Denmark. '4C-labelled thymidine (specific
activity 2.11 GBq mmol ') was obtained from Amersham.
Spectra/Por 3 (molecular weight cut-off 3,500) membrane
from Spectrum Medical Industries (Los Angeles, CA, USA)
was used as dialysis bag. Plastic flasks and plastic Petri dishes
used for tissue culture were from Nunclon (Nunc, Denmark)
and Falcon (Becton Dickinson, USA) respectively.
DDATHF treatment
DDATHF was dissolved in medium containing dialysed
serum immediately prior to use. The concentrations of
DDATHF tested in different experiments ranged between
1 nM and 1 gLM.
Several phase I clinical trials with DDATHF are in pro-
gress and we still do not know the maximal tolerated dose of
this drug. At a dose of 45 mg m-2 the plasma concentrations
of DDATHF ranged approximately from 20tLM to 0.2tLM
during the 24 h following drug infusion (D.R. Newell, per-
sonal communication). Therefore the concentrations used by
us were in a pharmacologically reasonable range.
Cell viability and clonogenicity
The effect of the drug on the cells was evaluated by a
standard clonogenic assay (Erba et al., 1992). One thousand
cells were plated in 3 ml of medium in 60 mm-diameter Petri
dishes. Cell viability was checked using erythrosin B. The
colonies were allowed to develop for 14 days. Plating
efficiency of the untreated, exponentially growing control
cells was between 85 and 90%. The colonies were stained
with 1% crystal violet solution in 20% ethanol and the
number of colonies and mean clone area were measured
using the IBAS 20 (Zeiss, Germany) image analysis system.
A background correction was done and the smallest size of
the control cell colony was taken as the minimum for setting
the cut-off point.
Flow cytometric analysis ofcell cycle phase distribution and
BrdU uptake
Monoparametric conventional cell cycle analysis using propi-
dium iodide (a specific fluorescent dye for DNA) was carried
out on control and treated cells at different times of drug
treatment and after drug washout using a FACStar plus
(Becton Dickinson) instrument coupled to a Hewlett Packard
computer system (Erba et al., 1992). Cell cycle phase percen-
tages were calculated by the method of Krishan and Frei
(1976).
For biparametric BrdU/DNA analysis (Sen et al., 1990),
30 JLM BrdU was added to the cells for 30 min at different
times during DDATHF treatment and after drug washout,
and fixed with 70% ethanol at 4°C. The cells were washed
with phosphate-buffered saline (PBS) and DNA was denatur-
ed with 3 M hydrochloric acid for 30min at room tempera-
ture. The denaturation was stopped by addition of 0.1 M
sodium borate (pH 8.5) in excess and the cells were cen-
trifuged. The cells were incubated for 15 min with a solution
of 0.5% Tween 20 in PBS and 1% normal goat serum. BrdU
uptake was detected after 1 h incubation with 100gd of anti-
BrdU monoclonal antibody diluted 1:10 in 0.5% Tween 20 in
PBS then another 1 h incubation with 100 gld of fluorescin-
conjugated goat anti-mouse IgG diluted 1:50 in 5% Tween
20 in PBS. After washing with PBS, the cells were resus-
pended in a solution of 5Lgml-' propidium iodide in PBS
and 10,000 U of ribonuclease for at least 2 h in the dark.
Flow cytometric immunofluorescence analysis on MOV18
MOV18 expression was detected in SW626 cells growing in
RPMI with 2.2lJM or without folic acid after 1 h incubation
with 100 gl of MOV18 antibody diluted 10 tgml-' in PBS
with 0.3% bovine serum albumin (BSA). After washing with
PBS, the cells were incubated for 1 h with 100gIl of fluo-
rescein-conjugated anti-mouse IgG developed in goats diluted
1:50 in 5% Tween 20 in PBS.
Alkaline elution
Exponentially growing cells were incubated with '4C-labelled
thymidine for 24 h. The radioactive label was removed and
the cells were chased for a further 24 h. DNA single-strand
breaks were assessed by alkaline elution methods slightly
modified previously (Kohn et al., 1981). DNA breaks were
assessed in parallel in samples X-irradiated with 300 rad as
positive controls.
Results
The clonogenic inhibitory effect of DDATHF is shown in
Figure 1. Dose-dependent inhibition was seen 14 days after
24h drug exposure. The IC50 was approximately 0.25 AM.
Continuous exposure to 1-50nM DDATHF for 48, 72, 96
or 192 h caused concentration- and time-dependent inhibition
of clonogenicity in sets receiving 5, 10, 25 or 50 nM
DDATHF (Figure 2). The concentration of 1 nM was not
active even after 192 h exposure. The cytotoxicity of all other
concentrations tested clearly increased with the exposure
time.
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Figure 1 Inhibition of clonogenicity of SW626 cells growing in
RPMI-1640 (containing 2.2 JM folic acid) supplemented with
10% dialysed fetal bovine serum by treatment with DDATHF
for 24 h. Clonogenic potential of exponentially growing untreated
control cells ranged between 85 and 90% of the cells plated,
which was normalised to 100%. Data are representative of at
least three independent experiments; each point is the mean of
three experiments; bar, standard error of the mean.MODULATION OF DDATHF CYTOTOXICITY 207
Figure 3 Effect of simultaneous hypoxanthine treatment on
0.5 jaM DDATHF-induced inhibition of clonogenicity of SW626
cells growing in RPMI-1640 (containing 2.2jiM folic acid) supple-
mented with 10% dialysed fetal bovine serum. Cells were treated
with 0.1, 1, 10 and 100gM hypoxanthine with DDATHF for 24 h
and colonies were allowed to develop for 14 days. Column, mean
of six replicates; bar, standard error of the mean. Clonogenicity
of control cells was normalised to 100%. -, 0.5gM DDATHF
treatment for 24 h; , 100 jiM hypoxathine treatment for 24 h;
1, 0.1 jM hypoxanthine together with 0.5gM DDATHF treat-
ment for 24 h; , 1IjM hypoxanthine together wth 0.5 jiM
DDATHF treatment for 24 h; E, 10jiM hypoxanthine together
with 0.5 jIM DDATHF treatment for 24 h; L-II, 100 jiM hypox-
anthine together with 0.5 jiM DDATHF treatment for 24 h.
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Figure 2 Effect of duration of treatment on SW626 cells growing
in RPMI-1640 (containing 2.2gM folic acid) supplemented with
10% dialysed fetal bovine serum. The cells were treated with 1, 5,
10, 25 and 50 nM DDATHF for 48, 72, 96 or 192 h and the
colonies were stained and counted on the 14th day after seeding.
Points are mean of six independent replicates; bar, standard error
of the mean. 0, 1 nM; *, 5 nM; *, 10nM; 0, 25 nM; A,
50 nM.
The drug has been reported to inhibit GAR transformyl-
ase, a major regulatory enzyme in de novo purine biosyn-
thesis. This causes a lack of inosinate, one of the main
precursors of purines. Addition of 100 ItM hypoxanthine
simultaneously with 0.5 jiM DDATHF reversed the inhibitory
effect of the drug-induced clonogenicity (Figure 3). A lower
concentration only partially reversed DDATHF cytotoxicity.
This indicates that the SW626 cells have a very large need for
purines when their synthesis is blocked by DDATHF. Ana-
lysis of size of colony shows that even at a high concentra-
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Figure 4 Cell cycle phase perturbation analysis by flow cytometry. a, Monoparametric (DNA) cell cycle analysis (lA-1lA) and
biparametric anti-BrdU immunofluorescence/DNA analysis (IB-11B). Cells treated with 0.5 iM DDATHF were analysed during
24h of drug treatment (2A,B-5A,B) or after drug washout and followed up to 72h (6A,b-1IA,B) in drug-free medium. At
specific points, cells were pulse labelled with 30 giM BrdU for 30 min, harvested, fixed in 70% ethanol and stained with anti-BrdU
antibody as described in detail in Materials and methods. T, drug treatment time; R, recovery time from drug treatment. b,
Percentages of S-phase cells (-) in the cell population and level of DNA synthesis (A) (mean anti-BrdU green fluorescence level)
of 0.5 gM DDATHF-treated cells during drug treatment (0-24 h) and after drug washout (28-96 h). Percentage of S-phase cells
(0) and level of DNA synthesis (A) of exponentially growing control cells are also shown. This experiment was performed on
SW626 cells growing in RPMI-1640 (containing 2.2 gM folic acid) supplemented with 10% dialysed fetal bovine serum.
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tion of hypoxanthine (100 JAM) the colonies were smaller than
controls, suggesting that adding hypoxanthine to the medium
is sufficient for colony formation but is not enough to restore
the normal growth rate of SW626 in the 2 weeks after
treatment (data not shown).
The drug-induced cell cycle perturbations and the level of
DNA synthesis are shown in Figure 4a. Monoparametric
DNA analysis (shown in the upper panels marked lA- lIA),
indicated that 0.5 JAM DDATHF treatment for 24 h decreased
the proportion ofcells in G2/M phases after an accumulation
in S-middle phase of the cell cycle, up to 72 h of recovery in
drug-free medium. DNA synthesis, as evaluated by uptake of
30 JAM BrdU at specific points during treatment and recovery
times, was established by biparametric BrdU/DNA flow cyto-
metric analysis as shown in Figure 4(1B-1lB). Between 4 h
(6B) and 24 h (9B) recovery time in drug-free medium, DNA
synthesis (BrdU level) progressively dropped to maximum
inhibition at 24 h recovery (9B). Between 48 and 72 h
recovery, the DNA synthesis rate became similar to exponen-
tially growing untreated control cells (1B). This effect is
graphically represented in Figure 4b.
The mechanism by which DDATHF-induced inhibition of
purine synthesis caused its cytotoxicity is unknown. Since the
inhibition of DNA synthesis appears transient and is restored
completely 48 h after DDATHF washout, the cytotoxicity
may not be directly related to the inhibition of DNA syn-
thesis.
The inhibition of thymidine synthesis by MTX or CB3717
was associated with the formation of DNA breaks, and the
inhibitor of protein synthesis, cycloheximide, prevented these
DNA breaks, also reducing the cytotoxicity of the drug
(Lorico et al., 1988). Therefore, it was of interest to verify
whether another antifolate that blocks purine biosynthesis
without affecting thymidine synthesis also caused DNA
damage and if cycloheximide could modify these DNA
breaks and drug-induced cytotoxicity. As shown in Figure 5,
DDATHF-induced DNA breaks were not detectable even
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after 48 h drug exposure, whereas under similar experimental
conditions MTX caused a significant number of DNA
breaks. Cycloheximide, 2.5 and 5JLM (inhibiting protein syn-
thesis by 50% and 90% respectively in 10 min, data not
shown), did not reverse the action of the drug after simul-
taneous application for 24 h. As shown-in Figure 6, cyclohex-
imide at the highest dose tested, 5 JAM for 24 h, did not affect
clonogenicity, indicating that inhibition of de novo protein
synthesis is not involved in drug-induced cytotoxicity.
In order to assess how the folic acid content of the
medium modified the clonogenic inhibitory effect of the drug,
we performed different experiments using cells conditioned to
grow in RPMI-1640 medium supplemented with 10% dialys-
ed FBS, without or with different concentrations of folic
acid. Figure 7 shows that the expression of mFBP assessed
by using MOV18 antibody increased significantly in SW626
cells growing in the absence of folic acid. As shown in Figure
8, 0.5 JM DDATHF treatment for 24h in total folic acid
(2.21JM) produced more than 60% inhibition of clonogeni-
city. In cells growing in 10-20 times less folic acid (0.22-
0.11 JAM), 5 nM DDATHF caused a similar level of inhibition.
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Figure 6 Effect of inhibition of protein synthesis for 24h on
0.5 ,LM DDATHF-induced inhibition of clonogenicity of SW626
cells growing in RPMI-1640 (containing 2.2iLM folic acid) supple-
mented with 10% dialysed fetal bovine serum. Cells were simul-
taneously treated with 2.5 ( 1 ) or 5 (LII )JAM, cycloheximide
and DDATHF for 24 h. , 5 JAM cycloheximide treatment;
M, 0.5 JAM DDATHF treatment. Column, mean of six repli-
cates; bar, standard error of the mean. Clonogenicity of control
cells was normalised to 100%.
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Figure 5 DNA single-strand break profile of DDATHF- and
MTX-treated SW626 cells growing in RPMI-1640 (containing
2.2JAM folic acid) supplemented with 10% dialysed fetal bovine
serum. *, control cells; 0, 10 JAM DDATHF treatment for 24 h
and 8 h drug washout; A, 10ILM DDATHF treatment for 24 h;
A, 10JAM DDATHF treatment for 48 h; 0, 10JAM methotrexate
treatment for 24h and 8 h drug washout; 0, 300 rad X-ray-
induced DNA breaks.
10° 101 102 103
MOV18 (green fluorescence)
104
Figure 7 Flow cytometric evaluation of the MFBP expression in
SW626 cells growing in RPMI-1640 supplemented with 10%
dialysed FBS with 2.2gM (---) or without (. ) folic acid.
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added simultaneously with the drug or immediately after
drug washout completely reversed the cytotoxic activity.
However, when folinic acid was added after 48 h or 72 h,
DDATHF still had cytotoxic activity similar to when it was
used alone. A concentration of folinic acid as low as 0.1 M
was sufficient to rescue the cytotoxicity of DDATHF when
given simultaneously. When folinic acid was given 24 h after
DDATHF a reversal of cytotoxicity was obtained at 0.5 and
1 tLM, but to a much lesser extent. As shown in Figure 10
folinic acid effect reached a plateau at 1 riM.
In order to assess the minimum time necessary for folinic
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Figure 8 Effect of folic acid in the medium on DDATHF-
induced inhibition of clonogenicity. The cells were treated for
24h with 1, 5, 10, 25, 50, 100, 500 and 1000nM DDATHF in
medium containing 2.27 (0), 0.22 (M), 0.11 (E) or 0.00 (0) JAM
folic acid and colonies were allowed to develop for 14 days.
Clonogenic potential of control cells was normalised to 100%.
When cells growing in folic acid-free medium were tested,
5 nM DDATHF completely inhibited their clonogenic poten-
tial.
Co-administration of folinic acid in vivo completely re-
versed the drug-induced systemic toxic manifestations in ex-
perimental animals (Grindey et al., 1992). To study the
modulation of the cytotoxic effect of DDATHF by folinic
acid, we incubated the cells with different DDATHF concen-
trations for 24 h. Folinic acid 10 AM was added either simul-
taneously during the drug treatment or 0, 24, 48 and 72 h
after DDATHF washout. Folinic acid was present through-
out the experiment up to harvest time. Folinic acid alone did
not inhibit clonogenicity of cells even at 1O,M. Concentra-
tions of 0.25, 0.5 and 1 JAM DDATHF inhibited clonogenicity
by 30, 55 and 85% respectively (Figure 9). Folinic acid 10 ,UM
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Figure 9 Modulation of the cytotoxic potential
10 JAM folinic acid on SW626 cells growing in F
taining 2.2 JAM folic acid) supplemented with 10
bovine serum. Cells were treated for 24 h with D
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drug washout and analysed 14 days later. Folin
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Figure 10 Modulation of the cytotoxic potential of 24 h treat-
ment of 0.5 JAM DDATHF by different concentrations of folinic
acid on SW626 cells growing in RPMI-1640 (containing 2.21JM
folic acid) supplemented with 10% dialysed fetal bovine serum.
Cells were treated with folinic acid simultaneously with DDATHF
(i), immediately after drug washout (0), or 24 h (0), 48 h (A)
or 72 h (A) after drug washout and analysed 14 days later.
Folinic acid 10 ILM for 24 h did not influence the cell clonogeni-
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S66cells growing in RPMI-1640 (containing 2.2JAM folinic
of DDATHF by acid) supplemented with 10% dialysed fetal bovine serum. Cells
IPMI-1640 (con- were treated with folinic acid simultaneously with DDATHF (A),
% dialysed fetal immediately after drug washout (B), and 24 h (C), 48 h (D) or
)DATHF (0) or 72 h (E) after drug washout and analysed 14 days later. Folinic
*), immediately acid for 24h even at a concentration of 10 JAM did not influence
or 72 h (A) after clonogenicity of the cells. Clonogenic potential of control cells
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acid to exert its modulatory effect, cells were treated for 24 h
with 0.5 JAM DDATHF and folinic acid at concentrations of
1, 5 or 1OJM was added for 2, 4, 6 or 24 h simultaneously
with the drug or 0, 24, 48 and 72 h after DDATHF washout.
Figure 11 summarises the results in 1 JAM folinic acid pulse
treatment since the results with 1, 5 and 10JAM folinic
acid were essentially the same. Given simultaneously with
DDATHF (columns marked A), folinic acid incubation for
as little as 2 h completely reversed the anti-tumour potential
of DDATHF. When administered immediately after 24 h
DDATHF treatment and left for at least 6h, folinic acid
markedly inhibited the anti-tumour effect of drug (columns
marked B). But 24 h exposure of folinic acid was essential to
reverse the cytotoxic potential of DDATHF when given 24 h
after DDATHF washout. Folinic acid added to the cells 48
or 72 h after drug washout for any period of time (2-24 h)
did not greatly influence the anti-tumour effect of DDATHF.
All these experiments strongly suggest that during the late
post-treatment periods a short or long pulse of folinic acid is
equally ineffective in reducing the cytotoxic potential of
DDATHF.
Discussion
The results presented confirm that the mode of action of the
antifolate DDATHF is distinct from other antifolates (Jansen
et al., 1991). DDATHF cytotoxicity has been related to the
drug's ability to inhibit purine biosynthesis. However, the
mechanism of cytotoxicity has still to be fully elucidated. In
SW626 cells exposed to DDATHF the inhibition of DNA
synthesis, consequent to the inhibition of de novo synthesis of
purines, only becomes evident after a few hours and does not
last long. This transient inhibition of DNA synthesis slows
the progression of cells towards S-phase, but does not ex-
plain the cytotoxicity.
For other antifolates such as methotrexate (MTX), it has
been proposed that cytotoxicity is due to the formation of
DNA breaks, presumably caused by uracil misincorporation
into DNA and/or activation of endonucleolytic enzymes (Li
& Kaminskas, 1984; Lorico et al., 1988). Since MTX inhibits
both thymidine and purine synthesis, it has been suggested
that the DNA fragmentation is triggered by the block of
DNA synthesis. However, since the addition of thymidine
abolishes the drug-induced DNA breakage and cytotoxicity
(Lorico et al., 1988), the effects may be due to thymidine
deprivation. This is further supported by the fact that inhi-
bitors of thymidylate synthase such as CB3717, which do not
affect purine biosynthesis but only thymidine synthesis, also
cause DNA breakage (Lorico et al., 1988). The inhibitor of
protein synthesis cycloheximide also inhibited MTX- or CB
3717-induced DNA breaks and cytotoxicity, suggesting that a
neosynthesised protein was implicated in the mechanism of
induction of DNA damage and cell death.
It was therefore of interest to study whether DDATHF,
which to our knowledge is the only antifolate acting as a
pure purine synthesis inhibitor, also induced DNA breakage
and whether the inhibition of protein synthesis reduced the
DNA damage and cytotoxicity. Our studies indicate that
DDATHF cytotoxicity is not mediated by DNA breaks and
that inhibition of protein synthesis does not modify the
drug's activity. DNA damage caused by the previously inves-
tigated antifolates is thus probably mainly due to thymidine
deprivation.
Although the mechanism of cell killing of DDATHF is
related to inhibition of purine biosynthesis, as hypoxanthine
blocked the effect, the drug-induced cell cycle perturbations
appeared moderate and reversible, thus excluding the possi-
bility that cytotoxicity is the consequence of prolonged
blockage of DNA biosynthesis. The decrease in intracellular
levels of either ATP or GTP might be the biochemical mech-
anism responsible for DDATHF cytotoxicity (Beardsley et
al., 1989; Kwok & Tattersall, 1992; Pizzorno et al., 1991b).
DDATHF has high affinity for membrane folate-binding proteins (mFBP) (Antony, 1992), suggesting that differences
in the expression of these proteins in neoplastic and normal
tissues might be exploited to achieve drug selectivity towards
some neoplasms (Jansen et al., 1989, 1991). For example, in
ovarian cancers mFBP, recognised by MOV18 and MOV19,
have been shown to be overexpressed (Miotti et al., 1987).
Preclinical animal studies have indicated that folic acid
strongly reduces the toxicity of DDATHF without markedly
inhibiting the anti-tumour activity (Alati et al., 1992; Grindey
et al., 1992). The concentrations of folic acid may be impor-
tant in the expression of mFBP and these effects may not be
the same in tumour and normal tissues.
In order to investigate the importance of the folic acid
concentration we have compared the cytotoxicity of
DDATHF in medium containing 2.2JAM folic acid and, after
appropriate adaptation, lower concentrations. In folic acid-
free medium the expression of mFBP, determined with the
antibody MOV18 (Campbell et al., 1991), was substantially
greater in SW626 cells (Figure 7), consistent with previous
reports on the regulation of mFBP expression (Antony,
1992). DDATHF sensitivity dramatically increased between
2.2 JAM and 0.22JAM folic acid, with about two logs of differ-
ence in the IC50 values. We do not know what is the explana-
tion for this increased sensitivity. The expression of mFBP
was in fact only marginally increased when cells were grown
in medium containing 0.22 AM folic acid compared with cells
grown in medium containing 2.2 JAM folic acid (data not
shown), thus suggesting that the change in drug sensitivity is
not due to an induction of mFBP. The concentration of
2.2 JAM, normally present in the culture medium, is approx-
imately 100 times the physiological values of folates in
human plasma, which are mainly present in the form of
5-methyltetrahydrofolate. Even with a folic acid-rich diet this
concentration cannot be achieved in vivo. At lower concen-
trations of folic acid, from 0 to 0.22 JAM, the differences in
DDATHF cytotoxicity were smaller, indicating that in a
physiological range the concentrations of folic acid only
weakly influenced the inhibition of DDATHF cytotoxicity
against these human ovarian cancer cells. When folic acid
concentrations were below 0.22 JAM a marked cytotoxicity of
DDATHF at concentrations of 5-10 nM was observed.
These concentrations of DDATHF can be achieved and
maintained in plasma ofpatients receiving tolerable DDATHF
dose (D.R. Newell, personal communication). This may be in
line with in vivo data showing that folic acid dramatically
reduced the toxicity but only marginally affected the anti-
tumour activity in mice (G.B. Grindey, personal communica-
tion) and provide a further experimental basis to investigate
the combination of folic acid and DDATHF in clinical use.
Another potentially clinically relevant aspect is whether,
and to what extent, the cytotoxic effects against tumour cells
are antagonised by folinic acid, normally used as an antidote
for high-dose MTX and under investigation as a modulator
of DDATHF toxicity (Pizzorno et al., 1990; Sessa et al.,
1992).
In this study folinic acid completely antagonised DDATHF
cytotoxicity when given simultaneously with DDATHF. The
antagonism might be due to inhibition of intracellular trans-
port, possibly by competition for the reduced folate carrier
mechanism, or for mFBP, although folinic acid has been
reported to have a low affinity for this high-affinity carrier.
When the simultaneous treatment lasted only 2 h and
DDATHF treatment was continued for a further 22 h after
drug washout without any more folinic acid added, the
antagonism persisted, possibly because the transport mechan-
ism was saturated by folinic acid.
Alternatively, folinic acid may inhibit DDATHF polyglut-
amylation, which increases both intracellular drug retention
and inhibitory potency on GAR transformylase. This is sup-
ported by previous findings in CCRF-CEM cells that folinic
acid can inhibit polyglutamylation of DDATHF when given
simultaneously with the drug. The same study, however,
showed that if folinic acid was given 4 h after DDATHF
there was no significant changes in the cellular content of the
polyglutamated forms. Therefore although the antagonism
observed on giving DDATHF and folinic acid simultane-MODULATION OF DDATHF CYTOTOXICITY 211
ously may be partly due to inhibition ofpolyglutamylation, it
appears unlikely that this mechanism explains the antago-
nism observed when folinic acid is given after 24 h exposure
to DDATHF. In this case it appears more likely that the
inhibition of GAR transformylase by DDATHF is abolished
by competition of the coenzyme, 10-methyltetrahydrofolate,
rapidly formed from folinic acid (Jansen et al., 1991).
The reversal of the inhibition would result in rapid restora-
tion of purine synthesis before the purine pools drop below a
threshold level and for long enough for toxicity to occur. If
the interval between DDATHF and folinic acid is longer (e.g.
48 or 72 h after DDATHF treatment) purine deprivation
below that threshold will probably last long enough to trig-
ger the mechanisms of cytotoxicity (still not known, as dis-
cussed above), and addition offolinic acid can no longer save
the already damaged cells.
Folinic acid is currently used in some protocols to antago-
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